EXAM 1 PHM 350 MSU QUESTIONS WITH CORRECT ANSWERS

EXAM 1 PHM 350 MSU QUESTIONS WITH
CORRECT ANSWERS

IN |the |figures |below |which |has |the |greater |potency?

Drug |A

B

C

D |- |CORRECT |ANSWER✔✔-Drug |B



Which |is |used |to |orthostatic |hypotension?

A. |isoprotenerenol |(ISUPREL)

B.Midodrine |(AMANTINE)

C. |brimonidine |(ALPHAGAN)

D. |Albuterol |(VENTOILIN)

E. |A |& |C |- |CORRECT |ANSWER✔✔-B. |MIDODRINE



Which |has |the |largest |therapeutic |window?

A: |Drug |A

B

C

D |- |CORRECT |ANSWER✔✔-Drug |D



Isoproterenol |(ISUPREL) |will |decrease |blood |pressure |by:

A: |activation |of |alpha |adreoreceptors |on |blood |vessels |of |the |skin |and |mesentery

,B. |activation |of |beta2 |adrenoreceptors |on |the |blood |vessels |of |skeletal |m

C: |blockage |of |alpha |1 |adrenoreceptors |on |blood |vessels |of |the |skin |and |mesentery

D: |Blockage |of |beta2 |adrenoreceptors |on |the |blood |vessels |of |skeletal |m

E: |none |of |these |- |CORRECT |ANSWER✔✔-B. |activation |of |beta2 |adrenoreceptors |on |the |blood
|vessels |of |skeletal |m




Drug |A |has |t1/2 |value |whihc |is |half |the |t1/2 |value |of |Drug |B. |IN |comparing |the |use |of |these |
drugs, |it |is |likely |that |Drug |A:

A: |is |more |likely |than |drug |B |to |produce |adverse |side |efects

B: |will |be |given |more |frequently |than |drug |B

C: |will |be |given |less |frequently |than |Drug |B

D: |A |& |B

E. |none |of |the |above |- |CORRECT |ANSWER✔✔-B: |will |be |given |more |frequently |than |drug |B



in |the |figure |below, |which |statement |best |fits |what |you |see?

A: |fo |the |response |being |measures, |Drugs |A |& |B |are |equally |potent

B: |Drug |A |is |les |potent |than |Drug |B

C: |Drugs |A&B |both |agonists |at |te |receptor |mediating |the |response |being |measured

D: |If |drugs |A |& |B |both |induce |this |effect |by |activating |same |type |of |receptor, |A |have |greater |
affinity

E: |A&C |- |CORRECT |ANSWER✔✔-E: |A&C



Bethanechol |(URECHOLINE)

A: |is |choline |ester |that |is |also |a |cholinomimetic

B: |has |a |high |affinity |for |nicotinic |cholinergic |receptors

C: |high |affinity |for |muscuarinic |cholinergic |receptors

D: |is |useful |therapeutically |bc |it |is |substrate |for |cholinesterases

, E: |A&C |- |CORRECT |ANSWER✔✔-E: |A&C



Liver |enzyme, |Z, |metabolizes |drug |A. |if |drug |A |is |administered |repeatedly, |then |the |amount |of |
Z |in |the |liver |increased. |Consequently.

A: |the |half |ife |of |drug |A |wil |be |increased

B: |the |hallife |of |drug |B |also |metabolizes |by |Z |will |not |be |affected

C: |half |life |of |all |drugs |metab |by |Z |will |be |decreased

D: |the |rate |of |metaboism |of |Drug |A |will |not |change

E: |A |&C |- |CORRECT |ANSWER✔✔-C: |half |life |of |all |drugs |metab |by |Z |will |be |decreased



therapeutic |threshold |concentration |of |a |drug

A: |is |affected |by |ability |fo |body |to |eliminate |the |drug

B: |the |minimu |plamsa |concentration |of |the |drug |which |is |required |to |induce |the |desired |
therapeutic |response

C: |depends |on |the |rate |of |absorption |of |the |drug

D: |determines |the |pharmacological |and |clinical |efficacies |of |the |drug

E: |A&C |- |CORRECT |ANSWER✔✔-B: |the |minimu |plamsa |concentration |of |the |drug |which |is |
required |to |induce |the |desired |therapeutic |response



Edrophonium |(TENSILON) |preferred |over |others |differentially |diagnose |myasthenia |gravis |from
|other |muscle |weakness |conditions |bc:



A: |its |a |Nm |nicotinic |receptor |agonist

B: |its |a |Nm |nicotinic |receptor |antagonist

C: |its |long |acting |cholinesterase |inhibitor

D: |its |short |acting |cholinesterase |inhibitor

E: |A&C |- |CORRECT |ANSWER✔✔-D: |its |short |acting |cholinesterase |inhibitor